- Tigermed reported a net income of 235.1 million yuan for the first quarter of 2024.
- The pharmaceutical company’s revenue for the period was a hefty 1.66 billion yuan.
- Market sentiment towards Tigermed remains predominantly positive with 20 buy ratings.
- However, caution is advised as there are 5 hold ratings indicating potential market uncertainties.
- Despite the substantial revenue, there are 3 sell recommendations signaling potential risk.
A look at Hangzhou Tigermed Consulting (A) Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 3 | |
| Growth | 4 | |
| Resilience | 4 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Hangzhou Tigermed Consulting (A) shows a promising long-term outlook based on the Smartkarma Smart Scores analysis. With solid scores in Growth, Resilience, and Momentum, the company seems well-positioned to capitalize on future opportunities in the clinical research industry. The Growth score of 4 indicates a positive trajectory for expansion, while the Resilience and Momentum scores of 4 each suggest a strong ability to weather economic challenges and maintain positive market performance. While Value and Dividend scores are slightly lower at 3, the overall picture points towards a company with growth potential and market resilience.
Hangzhou Tigermed Consulting Company Limited is a provider of professional clinical research services for both domestic and foreign pharmaceutical and health-related research and development. The company specializes in clinical trial technology services, data management, and statistical analysis. With encouraging Smartkarma Smart Scores in Growth, Resilience, and Momentum, Hangzhou Tigermed Consulting (A) appears to be well-equipped to navigate the evolving landscape of the healthcare and pharmaceutical industries in the long run.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
